Cardiometabolic & kidneySecondary analysis
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
- Secondary analysis of the SELECT randomised trial
- prespecified analysis
Authors' conclusion
In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. Weight loss was sustained over 4 years.
Study context
- Population
- Adults with preexisting CVD and overweight or obesity, without diabetes
- Participants
- 17,604 adults
- Comparison
- Semaglutide vs placebo
- Primary endpoint
- Weight and anthropometric outcomes, safety and tolerability by baseline BMI
- Follow-up
- 208 weeks
Primary result
As reported in the abstract
Weight, waist circumference, waist-to-height ratio
| Group | Weight | Waist circumference | Waist-to-height ratio |
|---|---|---|---|
| Semaglutide | −10.2% | −7.7 cm | −6.9% |
| Placebo | −1.5% | −1.3 cm | −1.0% |
- Semaglutide vs Placebo: P < 0.0001 — for all comparisons
Further findings
Weight loss trajectory
- With semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years
- Clinically meaningful weight loss in both sexes and all races, body sizes and regions
Safety
| Outcome | Semaglutide | Placebo |
|---|---|---|
| Serious adverse events (events per 100 years of observation), by BMI category · fewer serious adverse events with semaglutide | ||
| BMI <30 | 43.23 | 50.48 |
| BMI 30 to <35 | 43.54 | 49.66 |
| BMI 35 to <40 | 51.07 | 52.73 |
| BMI ≥40 | 47.06 | 60.85 |
Trial product discontinuation
- Increased rates with semaglutide; discontinuations increased as body mass index (BMI) class decreased
Original publication
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. Published 13 May 2024. doi:10.1038/s41591-024-02996-7
Summarised from the published abstract; every number is checked against it